BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33493001)

  • 1. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer.
    Cullen J; Lynch JA; Klein EA; Van Den Eeden SK; Carroll PR; Mohler JL; Knezevic D; Farrington TA; Lu R
    J Urol; 2021 Apr; 205(4):1047-1054. PubMed ID: 33493001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
    Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
    Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men.
    Murphy AB; Carbunaru S; Nettey OS; Gornbein C; Dixon MA; Macias V; Sharifi R; Kittles RA; Yang X; Kajdacsy-Balla A; Gann P
    Urology; 2020 Aug; 142():166-173. PubMed ID: 32277993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
    Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
    BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
    Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
    J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy.
    Falagario UG; Ratnani P; Lantz A; Jambor I; Dovey Z; Verma A; Treacy PJ; Sobotka S; Martini A; Bashorun H; Ashan M; Wagaskar VG; Lewis S; Cormio L; Carrieri G; Kyprianou N; Mohamed N; Tewari A
    J Urol; 2020 Jul; 204(1):82-90. PubMed ID: 31977261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
    Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
    Salmasi A; Said J; Shindel AW; Khoshnoodi P; Felker ER; Sisk AE; Grogan T; McCullough D; Bennett J; Bailey H; Lawrence HJ; Elashoff DA; Marks LS; Raman SS; Febbo PG; Reiter RE
    J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.
    Underwood W; Wei J; Rubin MA; Montie JE; Resh J; Sanda MG
    Urol Oncol; 2004; 22(1):20-4. PubMed ID: 14969799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
    Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
    Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.
    Yamoah K; Deville C; Vapiwala N; Spangler E; Zeigler-Johnson CM; Malkowicz B; Lee DI; Kattan M; Dicker AP; Rebbeck TR
    Urol Oncol; 2015 Feb; 33(2):70.e15-22. PubMed ID: 25304288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis.
    Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Saad F; Chun FK; Shariat SF; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Int J Urol; 2018 Nov; 25(11):929-936. PubMed ID: 30146729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy.
    Covas Moschovas M; Chew C; Bhat S; Sandri M; Rogers T; Dell'Oglio P; Roof S; Reddy S; Sighinolfi MC; Rocco B; Patel V
    Eur Urol Focus; 2022 Mar; 8(2):418-424. PubMed ID: 33757735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
    Kryvenko ON; Balise R; Soodana Prakash N; Epstein JI
    J Urol; 2016 Feb; 195(2):301-6. PubMed ID: 26341575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
    Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
    BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
    Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
    J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.